Summary A study has been carried out in which a comparison was made between EU lymphoma (assumed to be an insulin-producing secreting tumour) and thymoma (an insulin-dependent tumour). Tumour development and incidence, 3H-thymidine incorporation and insulin content in tumours, the host's food intake, blood insulin, glucose and cholesterol were determined in non-diabetic and alloxan-diabetic mice. Whereas no significant differences were observed between the diabetic and non-diabetic EL4 tumour-bearing mice, the diabetic, thymoma tumour-bearing mice showed reduced tumour growth and lower tumour incidence as compared with their non-diabetic counterparts. Insulin administration to diabetic tumour bearing mice, enhanced 3H-thymidine incorporation in the thymoma tumour cells only, and the insulin content of the EM tumours was found to be higher than that of the thymoma tumours. Rapid diabetes remission was observed in the diabetic, EL4 tumour-bearing mice as compared with the thymoma tumour-bearing mice.
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The involvement of insulin in malignancies is manifested in various ways such as increasing the uptake of glucose and other nutrients by cancer cells (Jehl et al., 1955) and stimulating DNA synthesis (Heuson et al., 1972; Lupulescu, 1983; Cohen & Hilf, 1974) . Disturbed glucose metabolism associated with hyperinsulinaemia in lung cancer patients and insulin resistance in other types of cancer is well documented (Bernshtein et al., 1985; Copeland et al., 1987; Lundholm et al., 1978) . Confficting observations have been reported regarding blood cholesterol and its possible relationship to cancer (De Waard, 1975; Fernleib 1983; McMichael et al., 1984) . Diabetes mellitus of type I, (deficient in insulin secretion) and type II (non-insulin-dependent diabetes mellitus) are generally associated with high plasma cholesterol level, despite low cholesterol synthesis. This phenomenon may be due to a decreased rate of cholesterol catabolism (Harper, 1965; Stolar, 1988 The early incidence of tumour was determined by positive or negative palpation.
Chemical analyses
Since the amount of blood obtained from a single mouse was insufficient for all determinations, blood collected from 10 mice was pooled, part of which was transferred to pre-cooled centrifuge tubes containing fluoride oxalate and centrifuged (1,500 r.p.m. for 10 min). The plasma glucose was determined by the glucose oxidase procedure on the same day, according to Pennock et al. (1973) .
After coagulation (2 h, 5C) the blood was centrifuged and the serum collected and frozen. Insulin level was determined in the pooled serum and in cell-free tissue extract which was prepared as follows: a weighed sample of tissue was triturated on a plastic net in PBS, centrifuged (2,000 g, 30 min, 5C, and the supernatant collected and frozen at -20C. Insulin was determined by a double antibody radio immunoassay, using '25I-labelled human insulin (Pharmacia Diagnostics AB, Uppsalla, Sweden). Total cholesterol was determined in serum by an enzymatic colorimetric method according to Siedel et al. (1983) Experiment 2: diabetic mice The experimental procedure was essentially the same as in experiment 1. Seven days before tumour transplantation diabetes was induced by alloxan injection. Mice were killed 0, 5, 12 and 20 days after tumour transplantation and, as in experiment 1, the last determination in the EL4 group was done 12 days after transplantation. In this experiment water intake was also determined. Insulin in tumours was determined 12 and 16 days after tumour transplantation in the EL4 and thymoma mice respectively.
Experiment 3
Diabetic mice were produced by alloxan injection, one week after which they were divided into four groups of five mice each. EL4 cells were transplanted in two groups and thymoma in the other two. Twelve days after EL4 transplantation and 16 days after thymoma transplantation, one of the tumour groups was injected subcutaneously with bovine insulin (Novo Ind., Copenhagen, Denmark; 21 100 g-1), 48, 24 and 3 h before killing and 3H-thymidine was also administered together with the last insulin injection (5 iLCi g-' in 0.2 ml saline, NEN, specific activity 28.5 Ci mmol -). At killing insulin was determined in part of the tumour tissue, and the remaining part and muscle from the left flank were weighed and homogenised, using a fritted glass Potter homogeniser. DNA was precipitated with 10% perchloric acid and washed twice with ethanol. Radioactivity was measured using a nuclear liquid scintillation system (Packard Tricarb) and insulin concentration and thymidine incorporation were also measured in the left flank of nondiabetic, non-tumour-bearing mice (NTB). Statistical analysis The differences between the trial means in each treatment group were tested for significance by one-way analysis of variance.
Results
Experiment 1: non-diabetic mice Food intake and body weight Body weight increased slightly but consistently in non-tumour bearing mice (NTB), in which food intake was constant during the experimental period ( Figure 1 ).
In the EL4 groups, tumour transplantation was followed by a consistent drop in body weight. However, from the second to the fourteenth days after transplantation, body weight increased linearly according to tumour dimensional growth and decreased thereafter, concomitantly with mortality. Consistent fluctuations were observed in food intake which decreased dramatically ten days after transplantation.
The thymoma groups displayed less effect after tumour transplantation than was seen in the EL4 groups, and body weight loss observed after tumour transplantation was gradually compensated for and reached, or slightly exceeded the weight of the control mice. Food intake exceeded that of the control groups up to 18 days post-transplantation, after which it dropped consistently. Blood plasma glucose, serum insulin and cholesterol Insulinaemia was much higher and glycaemia much lower in the tumour bearing mice than in the NTB (Figure 2 ). Insulinaemia tripled 4 days after transplantation, dropped moderately at 10 days and increased further thereafter in the EL4 groups, whereas in the thymoma mice, the increase was gradual and attained a peak 20 days after transplantation. In accordance with serum insulin level, plasma glucose was reduced far more in the EL4 mice than in those bearing thymoma.
Blood cholesterol gradually increased in the EL4 and decreased in the thymoma mice. In the NTB groups, the periodic variations were small and inconsistent (Figure 2 ). Experiment 2: diabetic mice Food and water intake and body weight In NTB mice, despite the important increase in food intake, alloxan-induced diabetes showed a consistent drop in body weight (Figure 3 ). Tumour transplantation was accompanied by a dramatic increase in body weight in the EL4 mice, and a more gradual increase in the thymoma mice. Alloxan-induced hyperphagia was gradually reduced after tumour transplantation to reach normal intake at the end of the experimental period. Water consumption was parallel to food intake, but doubled after diabetes induction and, in the tumour-bearing mice, gradually resumed the level observed before alloxan injection.
Blood plasma glucose, serum insulin and cholesterol Alloxan injection to NTB mice reduced insulinaemia by 60% (about 18 ;U ml-I in experiment 1 vs 6 lU ml-in the present experiment) and caused a dramatic increase in blood plasma glucose level (425 vs 125 mg 100 ml-') ( Figure 4 ). In the tumour-bearing diabetic mice, although blood insulin level was much higher than in the NTB counterparts, it was still lower than in normal mice and increased faster in the EL4 than the thymoma groups. Blood plasma glucose gradually decreased in the tumourbearing mice and reached almost normal levels 12 and 20 days after tumour transplantation in the EL4 and thymoma mice respectively.
Alloxan-induced diabetes affected total blood cholesterol very slightly when compared to the levels obtained in experiment 1. The trends caused by tumour transplantation observed in experiment 1 (i.e. increased cholesterolaemia in the EL4 mice and decreased cholesterolaemia in the thymoma mice) were repeated in the diabetic mice.
Whereas in EL4 mice, tumour incidence was not affected by alloxan-induced diabetes, it was consistently reduced in the diabetic thymoma mice as compared with non-diabetic mice (Figure 7) . in the muscle of the NTB non-diabetic mice and somewhere in between in diabetic thymoma tumour mice. Insulin administration was accompanied by a slight non-significant reduction in the tumour insulin concentration of the tumourbearing mice ( Figure 5 ).
3H-Thymidine incorporation in tumours Incorporation of 3H-thymidine into the muscle was slightly higher (nonsignificant) in the tumour-bearing mice than the controls ( Figure 6 ) and higher in the tumours of diabetic EL4 mice than thymoma mice. Insulin administration was accompanied by a dramatic increase in the incorporation of 3H-thymidine in the tumour of thymoma mice but did not affect the EL4 mice.
Discussion
Numerous studies have emphasised the phenomenon of 'cancer glucose' hunger and diabetic hyperglycaemia should therefore provide considerable advantages in cancer development. However, Pavelic & Slyjepcevic (1978) reported that murine thymoma grew more slowly in diabetic mice and that such mice had a significantly longer survival period than the non-diabetic controls. The authors suggest a tumour insulindependency.
Thymoma tumour The present study reinforces the above suggestion in the light of lower tumour incidence observed in final stages (38 vs 90%) in diabetic than non-diabetic mice (Figure 7) , as well as the slower increase in tumour weight as reflected by body weight (Figure 3 ), (the authors unpublished results indicate that the weight of dissected tumours varied between 1 and 6 g and was related to body weight) and by the enhanced thymidine incorporation into cancer cells after insulin administration ( Figure 6) .
A direct effect of alloxan on tumour cells does not seem to account for these observations, since half its biological life is only one hour (Rerup, 1968) . Like thymoma, other tumours have been reported to be insulin dependent. These are: MCF-7 human breast cancer (Shafic & Liotta, 1980) , respiratory cancer in human male (Kesler, 1970) , rat mammary adenocarcinoma (Puckitt & Shagleton, 1972) , or carcinoma (Heuson & Legros, 1970) , rat hepatoma (Salzberg & Griffin, 1952) , rat Novikoff hepatoma (Goranson et al., 1954) , rat Walker carcinoma (Goranson & Tilser, 1955) , murine mammary carcinoma (Puckitt & Shagleton, 1972) , Erlich tumour (Pavelic et al., 1979) , Erlich ascites carcinoma in mice (Fung et al., 1985) . Several of these tumours might cause remission Non-diabetic. Goranson & Tilser, 1955; Pavelic et al., 1979) . The increased cell glucose uptake was attributed to the ability of these tumours to stimulate insulin secretion from host pancreatic P-cells (Pavelic & Slyjepcevic, 1978) , and/or to maintain the hormone, probably due to high receptor density. Other factors having insulin-like activity cannot be discounted and remain undetermined. The reduction in blood insulin observed 24 days after transplantation in thymoma bearing mice (Figure 2 ), which did not show a concomitant increase in plasma glucose, may be due to less food intake and pancreatic insulin production, accompanied by an increase in tumour glucose demands.
EL4 tumour
In the present study the EL4-bearing mice were characterised by high blood insulin levels (even before tumour could be detected (Figures 2 and 4) and by regular tumour development, manifested by the increase in body weight (Figures 1  and 3 ) of diabetic as compared to non-diabetic mice. Furthermore, earlier tumour detection in the diabetic mice ( Figure 7) suggests favourable conditions for tumour development in its early stage.
High rate of diabetes remission (Figures 2 and 4) , enhanced thymidine incorporation in tumour cells, with or without insulin administration (Figure 6 ), and high insulin content in EL4 tumour tissue was also observed in nondiabetic and alloxan-diabetic mice ( Figure 5 ). Although these observations suggest that EL4 is probably an insulinproducing secreting tumour, direct proof of insulin production by EL4 tumour cells remain undetermined. The absence of hypoinsulinaemia in agonising mice (as compared to the thymoma mice; Figure 2 ) reinforces this suggestion.
Many tumours have been reported to be insulin-producing/ secreting in humans, such as: insulinoma (Yoshinobu et al., 1985) , cervix carcinoma and corpus uteri carcinoma (Pavelic et al., 1982a) , mammary and bronchial carcinoma (Greenberg et al., 1968) , thoracic sarcomata and fibrosarcoma (Linscheer et al., 1967) , renal adenocarcinoma (Pavelic & Pavelic, 1981 ). Hodgkin's and non-Hodgkin's lymphoma (Pavelic et al., 1982b; Pavelic & Vuk-Pavlovic, 1983) . The above applies also to experimental animals: murine B16 melanoma (Bajzer et al., 1984) , myeloid leukaemia (Graham, 1986) and aplastic carcinoma (Hyrayama, 1978) . Hobbs & Miller (1967) Days after tumour transplantation Figure 7 Tumour detection (% in population) in EM4 or thymoma tumour-bearing, diabetic (trials 1-3, experiment 2) and non-diabetic mice (trials 1-3, experiment 1). EL4, days 6, 8 and 10; thymoma, days 16, 18 and 20 after tumour transplantation. Data analysed by t test between trials of experiments 1 and 2 were significant at days 8 (EL4), 18 and 20 (thymoma); P<0.01. -Non-diabetic. E Diabetic.
insulin-like substances in the plasma of tumour-bearing humans (Chowddhury & Bleicher, 1973; Shapot, 1972) . It is thought that hyperinsulinaemia evokes an 'insulin receptor down regulation' (Baldwin et al., 1981; Mountjoy et al., 1983) , as well as a sharp decrease in the insulin binding capacity (Gammeltoft, 1984) , or disturbed glucose metabolism and insulin resistance (Bernshtein et al., 1985; Copeland et al., 1987; Lundholm et al., 1978) . However, all these phenomena are virtually absent in some human tumour cells (Mountjoy et al., 1983 (Mountjoy et al., , 1987 , making them metabolically superior to normal cells. The real significance of these observations reveals that the host's blood nutrients, in hyperinsulinaemic status, are more predisposed to tumour cells than non-malignant normal cells.
Contradictory studies have been reported on the relationship between blood cholesterol and cancer development. The possible cholesterol involvement in cancer is indicated by the fact that its oxidation products are known to be carcinogenic (Bischoff, 1969) and mutagenic (Smith et al., 1979) . Further reports show that increased serum cholesterol is associated with breast cancer which is more common in overweight women (De Waard, 1975) and also associated with high animal fat intake (Armstrong & Doll, 1975; Hems, 1978; Miller et al., 1978; Drasar & Irving, 1973) . Preliminary analyses of data indicated that dietary cholesterol and fat are significantly associated with human lung cancer risk (Kolonel et al., 1981; Hinds et al., 1982) and cancer in mice (Szepsenwol, 1966) . On the other hand, several recent epidemiological studies have found serum cholesterol to be inversely related to cancer risk in colon and gastric carcinoma incidence (Fernleib, 1983; McMichael et al., 1984; Cambien et al., 1980; Beaglehole et al., 1980; Kark et al., 1980) . Other studies have found no association (Dyer et al., 1981; Yaari et al., 1981) , and although several authors propose that hypocholesterolaemia is a predisposing factor to cancer development (Cambien et al., 1980) , no causative relationship has been so far established, which led Rose and Shipley (1980), McMichael et al. (1984) and Alexopoulos et al. (1987) to conclude that low plasma cholesterol is secondary to malignant disease.
The present study, which has been carried out on two different tumours, does not elucidate the relationship between cholesterol and cancer. However, it is possible that since cholesterol metabolism is profoundly affected by insulin (Harper, 1965; Stolar, 1988) , abnormal blood plasma cholesterol in tumour-bearing subjects may be secondary to abnormal insulin regulation and metabolism in malignancies.
Data on the insulin-cholesterol relationship are scarce, especially in cancer-bearing subjects and merit further investigation. Additional data on insulin-tumour relationships would enable a detailed classification of tumours and host-tumour metabolic dependencies, which would lead to more efficient preventive treatment and measures.
